Evidence map›Paper›PMID 31300920›Full record

ReviewCurrent neurology and neuroscience reports2019

Diabetes Therapies for Dementia.

Chris Moran, Michele L Callisaya, Velandai Srikanth, Zoe Arvanitakis

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Validity of Montreal Cognitive Assessment to Detect Cognitive Impairment in Individuals with Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. The Relation of Diabetes to Memory Function.Current neurology and neuroscience reports · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Chris MoranPeninsula Clinical School, Central Clinical School, Monash University, 2 Hastings Road, Frankston, VIC, 3199, Australia.
Michele L CallisayaPeninsula Clinical School, Central Clinical School, Monash University, 2 Hastings Road, Frankston, VIC, 3199, Australia.
Velandai SrikanthPeninsula Clinical School, Central Clinical School, Monash University, 2 Hastings Road, Frankston, VIC, 3199, Australia.
Zoe ArvanitakisDepartment of Neurological Sciences, Rush Memory Clinic, Rush Alzheimer's Disease Center, Rush University Medical Center, 1750 W. Harrison Street, Suite 1000, Chicago, IL, 60612, USA. Zoe_Arvanitakis@rush.edu.
Monash University · AUPeninsula Health · AURush University Medical Center · USUniversity of Tasmania · AU

Funding

Linking peripheral and brain insulin resistance to AD neuropathology and cognitionRF1AG059621 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI AHIMA, REXFORD S., ARNOLD, STEVEN E · 2018 to 2018
$3.8M
NIA NIH HHS RF1 AG059621
6 · The paper itself

Abstract

purpose of reviewType 2 diabetes (T2D) is a well-established risk factor for the development of dementia. Dementia and T2D share some underlying pathophysiology that has led to interest in the potential to repurpose drugs used in the management of T2D to benefit brain health. This review describes the scientific data available on the use of T2D medications for the risk reduction or management of dementia, in people with and without T2D. RECENT

findingsResults from basic laboratory research support the potential for commonly-used medications for T2D, including those with direct glucose-lowering properties, to have a beneficial effect on brain health. However, human studies have been mostly observational in nature and report conflicting results. Preliminary data suggest that intranasal insulin, metformin, and GLP-1 agonists show promise for dementia, but confirmatory evidence for their benefit in dementia is still lacking. Current evidence does not support the repurposing of T2D medications for dementia risk reduction or management. Research in the field of T2D and dementia is active, and further data are required before definitive conclusions can be drawn.

Indexed as

Drug RepositioningBlood GlucoseBrainDementiaDiabetes Mellitus, Type 2HumansHypoglycemic AgentsInsulinRisk FactorsBlood GlucoseHypoglycemic AgentsInsulinDementiaDrugsType 2 diabetes

Identifiers

PMID31300920
OpenAlexW2956665190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.